Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Trientine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 7/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | CA6 | P23280 | 3/20 | 0.58 |
| ▸ | CA7 | P43166 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA3 | P07451 | 2/20 | 0.58 |
| ▸ | CA4 | P22748 | 2/20 | 0.58 |
| ▸ | CA5A | P35218 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trientine SCHEMBL505672 | 1.00 | LMNA (0.58) | LMNACA12CA6CA7CA9 | |
| Trientine SCHEMBL14343015 | 1.00 | LMNA (0.58) | LMNACA12CA6CA7CA9 | |
| Succinic Acid SCHEMBL2447637 | 1.00 | LMNA (0.58) | LMNACA12CA6CA7CA9 | |
| Succinic Acid SCHEMBL2449729 | 0.97 | LMNA (0.57) | LMNACA12CA6CA7CA9 | |
| Succinic Acid SCHEMBL3778716 | 0.97 | LMNA (0.57) | LMNACA12CA6CA7CA9 | |
| SCHEMBL18814471 | 0.92 | LMNA (0.55) | LMNACA12CA6CA7CA9 | |
| Adipic Acid SCHEMBL11873219 | 0.92 | NFKB1 (0.64) | LMNACA12CA6CA7CA9 | |
| Trientine SCHEMBL11876109 | 0.92 | NFKB1 (0.64) | LMNACA12CA6CA7CA9 | |
| SCHEMBL16638651 | 0.92 | LMNA (0.55) | LMNACA12CA6CA7CA9 | |
| Adipic Acid SCHEMBL4681431 | 0.92 | NFKB1 (0.64) | LMNACA12CA6CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114312-A1 | TREATMENT OF COPPER DISORDERS | PHILERA NEW ZEALAND LTD. (NZ) | 2025-04-10 | — | — | US | claimed |
| EP-4511013-A1 | TREATMENT OF BRAIN COPPER DISORDERS | Philera New Zealand Ltd. (NZ) | 2025-02-26 | — | — | EP | claimed |
| CN-119522094-A | Treatment of brain copper disorders | 菲勒拉新西兰有限责任公司 | 2025-02-25 | — | — | CN | claimed |
| EP-4301350-A1 | TREATMENT OF COPPER DISORDERS | Philera New Zealand Ltd. (NZ) | 2024-01-10 | — | — | EP | claimed |
| CN-117157064-A | Treatment of copper disorders | 菲勒拉新西兰有限责任公司 | 2023-12-01 | — | — | CN | claimed |
| US-20230364031-A1 | TREATMENT OF BRAIN COPPER DISORDERS | PHILERA NEW ZEALAND LTD. (NZ) | 2023-11-16 | — | — | US | claimed |
| WO-2023203378-A1 | TREATMENT OF BRAIN COPPER DISORDERS | COOPER GARTH (NZ) | 2023-10-26 | — | — | WO | claimed |
| US-11795150-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2023-10-24 | — | — | US | claimed |
| US-20220331275-A1 | COMBINATION TREATMENTS FOR CENTRAL NERVOUS SYSTEM DISORDERS | PHILERA NEW ZEALAND LTD. (NZ) | 2022-10-20 | — | — | US | claimed |
| WO-2022187702-A1 | PREVENTION AND TREATMENT OF CORONAVIRUS AND RELATED RESPIRATORY INFECTIONS | PHILERA NEW ZEALAND (NZ) | 2022-09-09 | — | — | WO | claimed |
| WO-2022187709-A1 | TREATMENT OF COPPER DISORDERS | PHILERA NEW ZEALAND (NZ) | 2022-09-09 | — | — | WO | claimed |
| US-20220280451-A1 | TREATMENT OF COPPER DISORDER | PHILERA NEW ZEALAND LTD. (NZ) | 2022-09-08 | — | — | US | claimed |
| US-20220280450-A1 | PREVENTION AND TREATMENT OF CORONAVIRUS AND RELATED RESPIRATORY INFECTIONS | PHILERA NEW ZEALAND LTD. (NZ) | 2022-09-08 | — | — | US | claimed |
| CN-114867474-A | Combination therapy for central nervous system disorders | 菲勒拉新西兰有限责任公司 | 2022-08-05 | — | — | CN | claimed |
| EP-3982943-A1 | COMBINATION TREATMENTS FOR CENTRAL NERVOUS SYSTEM DISORDERS | Philera New Zealand Ltd. (NZ) | 2022-04-20 | — | — | EP | claimed |
| EP-1778618-A4 | SYNTHESIS OF TRIETHYLENETETRAMINES | PROTEMIX CORP LTD (NZ) | 2008-07-16 | — | — | EP | claimed |
| EP-1778618-A2 | SYNTHESIS OF TRIETHYLENETETRAMINES | Protemix Corporation Limited (NZ) | 2007-05-02 | — | — | EP | claimed |
| WO-2006027705-A2 | SYNTHESIS OF TRIETHYLENETETRAMINES | PROTEMIX CORPORATION LIMITED (NZ) | 2006-03-16 | — | — | WO | claimed |
| US-20060041170-A1 | starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride | PHILERA NEW ZEALAND LIMITED (NZ) | 2006-02-23 | — | — | US | claimed |
| CN-119529194-B | Macromolecular anticancer drug and preparation method of controllable molecular weight thereof | TSINGHUA UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4565559-A1 | METHOD FOR TRIETHYLENETETRAMINE PURIFICATION | Philera New Zealand Ltd. (NZ) | 2025-06-11 | — | — | EP | disclosed |
| CN-119968353-A | Triethylenetetramine purification process | 菲勒拉新西兰有限责任公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250114312-A1 | TREATMENT OF COPPER DISORDERS | PHILERA NEW ZEALAND LTD. (NZ) | 2025-04-10 | — | — | US | disclosed |
| US-20250114312-A1 | TREATMENT OF COPPER DISORDERS | PHILERA NEW ZEALAND LTD. (NZ) | 2025-04-10 | — | — | US | disclosed |
| CN-119529194-A | Macromolecular anticancer drug and preparation method of controllable molecular weight thereof | 清华大学 | 2025-02-28 | — | — | CN | disclosed |
| EP-4511013-A1 | TREATMENT OF BRAIN COPPER DISORDERS | Philera New Zealand Ltd. (NZ) | 2025-02-26 | — | — | EP | disclosed |
| CN-119522094-A | Treatment of brain copper disorders | 菲勒拉新西兰有限责任公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12076340-B2 | Use of trientine to deliver copper to ischemic tissue | INNOLIFE CO., LTD. (CN) | 2024-09-03 | — | — | US | disclosed |
| WO-2024033786-A1 | METHOD FOR TRIETHYLENETETRAMINE PURIFICATION | PHILERA NEW ZEALAND LTD. (NZ) | 2024-02-15 | — | — | WO | disclosed |
| US-20240043370-A1 | METHOD FOR TRIETHYLENETETRAMINE PURIFICATION | PHILERA NEW ZEALAND LTD. (NZ) | 2024-02-08 | — | — | US | disclosed |
| EP-4301350-A1 | TREATMENT OF COPPER DISORDERS | Philera New Zealand Ltd. (NZ) | 2024-01-10 | — | — | EP | disclosed |
| EP-4301350-A1 | TREATMENT OF COPPER DISORDERS | Philera New Zealand Ltd. (NZ) | 2024-01-10 | — | — | EP | disclosed |
| CN-117338762-A | Use of trientine to deliver copper to ischemic tissue | 北京因诺瑞康生物医药科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117157064-A | Treatment of copper disorders | 菲勒拉新西兰有限责任公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117157064-A | Treatment of copper disorders | 菲勒拉新西兰有限责任公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230364031-A1 | TREATMENT OF BRAIN COPPER DISORDERS | PHILERA NEW ZEALAND LTD. (NZ) | 2023-11-16 | — | — | US | disclosed |
| WO-2023203378-A1 | TREATMENT OF BRAIN COPPER DISORDERS | COOPER GARTH (NZ) | 2023-10-26 | — | — | WO | disclosed |
| US-11795150-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2023-10-24 | — | — | US | disclosed |
| CN-108697669-B | Use of trientine to deliver copper to ischemic tissue | 北京因诺瑞康生物医药科技有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20220331275-A1 | COMBINATION TREATMENTS FOR CENTRAL NERVOUS SYSTEM DISORDERS | PHILERA NEW ZEALAND LTD. (NZ) | 2022-10-20 | — | — | US | disclosed |
| WO-2022187702-A1 | PREVENTION AND TREATMENT OF CORONAVIRUS AND RELATED RESPIRATORY INFECTIONS | PHILERA NEW ZEALAND (NZ) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022187709-A1 | TREATMENT OF COPPER DISORDERS | PHILERA NEW ZEALAND (NZ) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022187709-A1 | TREATMENT OF COPPER DISORDERS | PHILERA NEW ZEALAND (NZ) | 2022-09-09 | — | — | WO | disclosed |
| US-20220280451-A1 | TREATMENT OF COPPER DISORDER | PHILERA NEW ZEALAND LTD. (NZ) | 2022-09-08 | — | — | US | disclosed |
| US-20220280451-A1 | TREATMENT OF COPPER DISORDER | PHILERA NEW ZEALAND LTD. (NZ) | 2022-09-08 | — | — | US | disclosed |
| US-20220280450-A1 | PREVENTION AND TREATMENT OF CORONAVIRUS AND RELATED RESPIRATORY INFECTIONS | PHILERA NEW ZEALAND LTD. (NZ) | 2022-09-08 | — | — | US | disclosed |
| CN-114867474-A | Combination therapy for central nervous system disorders | 菲勒拉新西兰有限责任公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3982943-A1 | COMBINATION TREATMENTS FOR CENTRAL NERVOUS SYSTEM DISORDERS | Philera New Zealand Ltd. (NZ) | 2022-04-20 | — | — | EP | disclosed |
| US-20200148647-A1 | Synthesis of Triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2020-05-14 | — | — | US | disclosed |
| US-20170226064-A1 | Synthesis of Triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2017-08-10 | — | — | US | disclosed |
| US-9556123-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2017-01-31 | — | — | US | disclosed |
| US-20160102060-A1 | Synthesis of Triethylenetetramines | PROTEMIX CORPORATION LIMITED (NZ) | 2016-04-14 | — | — | US | disclosed |
| US-20150057466-A1 | Synthesis of Triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2015-02-26 | — | — | US | disclosed |
| US-8912362-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2014-12-16 | — | — | US | disclosed |
| US-20130345311-A1 | Synthesis Of Triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2013-12-26 | — | — | US | disclosed |
| EP-1778618-B1 | SYNTHESIS OF TRIETHYLENETETRAMINES | PHILERA NEW ZEALAND LTD (NZ) | 2013-12-25 | — | — | EP | disclosed |
| US-8394992-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2013-03-12 | — | — | US | disclosed |
| US-20120029203-A1 | Synthesis Of Triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2012-02-02 | — | — | US | disclosed |
| US-8067641-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2011-11-29 | — | — | US | disclosed |
| US-20100173994-A1 | Synthesis of triethylenetetramines | PROTEMIX CORPORATION LIMITED (NZ) | 2010-07-08 | — | — | US | disclosed |
| US-7582796-B2 | starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride | PROTEMIX CORPORATION LIMITED (NZ) | 2009-09-01 | — | — | US | disclosed |
| EP-1778618-A4 | SYNTHESIS OF TRIETHYLENETETRAMINES | PROTEMIX CORP LTD (NZ) | 2008-07-16 | — | — | EP | disclosed |
| EP-1778618-A2 | SYNTHESIS OF TRIETHYLENETETRAMINES | Protemix Corporation Limited (NZ) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006027705-A2 | SYNTHESIS OF TRIETHYLENETETRAMINES | PROTEMIX CORPORATION LIMITED (NZ) | 2006-03-16 | — | — | WO | disclosed |
| US-20060041170-A1 | starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride | PHILERA NEW ZEALAND LIMITED (NZ) | 2006-02-23 | — | — | US | disclosed |
| US-20030109400-A1 | Care booster composition for supplementing the performance of laundry compositions | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-06-12 | — | — | US | disclosed |
| WO-2003038023-A1 | CARE BOOSTER COMPOSITION FOR SUPPLEMENTING THE PERFORMANCE OF LAUNDRY COMPOSITIONS | UNILEVER PLC (GB) | 2003-05-08 | — | — | WO | disclosed |
| US-6451749-B1 | REDUCING WRINKLES IN A FABRIC BEING WASHED. THE CARE BOOSTER COMPOSITION ENHANCES THE PERFORMANCE OF LAUNDRY DETERGENTS AND FABRIC CONDITIONERS AND MAY BE USED IN PROCESSES FOR CLEANING CLOTHS. | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-09-17 | — | — | US | disclosed |
| US-6451749-B1 | REDUCING WRINKLES IN A FABRIC BEING WASHED. THE CARE BOOSTER COMPOSITION ENHANCES THE PERFORMANCE OF LAUNDRY DETERGENTS AND FABRIC CONDITIONERS AND MAY BE USED IN PROCESSES FOR CLEANING CLOTHS. | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795150-B2 | Synthesis of triethylenetetramines | PNMT, TES, TPR | SLC6A2 320/4885LMNA 2638/4885CA12 3847/4885 |
| US-20160102060-A1 | Synthesis of Triethylenetetramines | PNMT, TES, TPR | SLC6A2 320/4885LMNA 2638/4885CA12 3847/4885 |
| US-20170226064-A1 | Synthesis of Triethylenetetramines | PNMT, TES, TPR | SLC6A2 320/4885LMNA 2638/4885CA12 3847/4885 |
| US-12076340-B2 | Use of trientine to deliver copper to ischemic tissue | HIF1A, HIF1AN, P4HA1 | SLC6A2 2018/4885LMNA 4464/4885CA12 2827/4885 |
| US-20130345311-A1 | Synthesis Of Triethylenetetramines | PNMT, TES, TPR | SLC6A2 320/4885LMNA 2638/4885CA12 3847/4885 |
| US-20120029203-A1 | Synthesis Of Triethylenetetramines | PNMT, TES, TPR | SLC6A2 320/4885LMNA 2638/4885CA12 3847/4885 |
| US-20150057466-A1 | Synthesis of Triethylenetetramines | PNMT, TES, TPR | SLC6A2 320/4885LMNA 2638/4885CA12 3847/4885 |
| US-20200148647-A1 | Synthesis of Triethylenetetramines | PNMT, TES, TPR | SLC6A2 320/4885LMNA 2638/4885CA12 3847/4885 |
| US-20060041170-A1 | starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride | TET1, TET2, TET3 | SLC6A2 1640/4885LMNA 2754/4885CA12 1751/4885 |
| US-20100173994-A1 | Synthesis of triethylenetetramines | PNMT, TES, TPR | SLC6A2 320/4885LMNA 2638/4885CA12 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.